|
Baseline Clinical Characteristics and Laboratory Values of Subjects |
||||
| All (n = 23) |
Non-survivors (n = 15) |
Survivors (n = 8) |
P value |
|
|
|
||||
| Male/female |
11 M; 12 F |
7 M; 8 F |
4 M; 4 F |
NS |
| Age |
62.6 ± 4.0 |
61.4 + 5.5 |
64.8 ± 5.6 |
NS |
| Mechanical ventilation |
17/23 |
13/15 |
4/8 |
NS |
| PO2/FiO2 |
171.8 ± 20.8 |
147.2 ± 21.1 |
217.9 ± 42.4 |
NS |
| Pressor use |
20/23 |
13/15 |
7/8 |
NS |
| Dopamine dose (μg/kg/min) |
6.8 ± 1.6 |
7.6 ± 2.5 |
5.9 + 1.8 |
NS |
| Norepinephrine dose (μg/kg/min) |
0.22 ± 0.05 |
0.17 ± 0.05 |
0.30 ± 0.10 |
NS |
| Number of organ failures |
5.3 ± 0.3 |
5.9 ± 0.3 |
4.3 ± 0.5 |
0.0138 |
| APACHE II |
27.3 ± 1.5 |
28.9 ± 1.8 |
24.4 ± 2.6 |
NS |
| SAPS |
55.2 ± 2.8 |
61.5 ± 11.3 |
43.4 ± 2.7 |
0.0002 |
| Serum creatinine (mg/dL) |
2.4 ± 0.3 |
2.4 ± 0.4 |
2.4 ± 0.5 |
NS |
| Serum albumin (g/dL) |
2.3 ± 0.1 |
2.2 ± 0.1 |
2.7 ± 0.2 |
0.0498 |
| Serum bilirubin (mg/dL) |
3.2 ± 1.2 |
4.5 ± 1.7 |
0.7 ± 0.1 |
0.0444 |
| Platelets (× 103 per uL) |
171 ± 32 |
119 ± 31 |
269 ± 60 |
0.0483 |
| PT |
15.9 ± 0.7 |
17.1 ± 0.9 |
13.8 ± 0.7 |
0.0069 |
| Serum lactate (mmol/L) |
2.7 ± 0.3 |
2.9 ± 0.5 |
2.5 ± 0.5 |
NS |
| Bacteraemia |
10/23 |
7/15 |
3/8 |
NS |
| Organisms |
4 S. aureus 3 E.coli 1 S. pneumoniae 1 P. mirabilis 1 C. albicans |
4 S. aureus 1 E. coli 1 P. mirabilis 1 C. albicans |
2 E. coli 1 S. pneumoniae |
|
| Underlying disorder |
5 post-op 4 cancer 2 diabetes 1 each pancreatitis, sickle cell crisis, AIDS, CVA, trauma, cirrhosis, dementia, epilepsy 4 nil |
4 post-op 4 cancer 1 each pancreatitis, sickle cell crisis, AIDS, CVA, trauma, cirrhosis, nil |
3 nil 2 diabetes 1 each post-op, dementia, epilepsy |
|
| Clinical infection |
13 pneu 5 bsi 2 uti 2 peritonitis 1 ssti |
7 pneu 5 bsi 1 uti, ssti, peritonitis |
6 pneu 1 uti 1 peritonitis |
|
Kumar et al. Critical Care 2008 12:R35 doi:10.1186/cc6814 |
||||